Clinical Data AZ claims another win for Imfinzi in frontline liver cancer PharmaphorumAstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.Clinical DataOncologyRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. Clinical DataOncologyRead full story Post navigation Previous: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesityNext: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
